Pharmacogenomics. Social, Ethical, and Clinical Dimensions - Hardcover

 
9780471227694: Pharmacogenomics. Social, Ethical, and Clinical Dimensions
Hardcover
ISBN 10: 0471227692 ISBN 13: 9780471227694
Verlag: Wiley-Liss, 2003

Inhaltsangabe

Through analyses of the complex underlying issues, this interdisciplinary volume frames the agenda for dealing with genetic variation and incorporating pharmacogenomics into health care. The three sections of this book, Research Issues, Clinical Issues, and Social Perspectives  address key elements integral to a comprehensive discussion of this emerging field.

This groundbreaking text…

  • Examines new research strategies, methodologies, and ethical and social considerations of pharmacogenomics
  • Addresses practical considerations of anticipated changes in education, training, oversight, guidelines and protocols, and continuing education requirements
  • Provides analyses of the potential enormous impact of pharmacogenomics, such as in the standard of care and treatment, including perspectives from the fields of anthropology, law, ethics, and economics

Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.

Über die Autorin bzw. den Autor

Mark A. Rothstein holds the Herbert F. Boehl Chair of Law and Medicine and is Director of the Institute for Bioethics, Health Policy and Law at the University of Louisville. He has appointments in the Departments of Medicine and Family and Community Medicine at the School of Medicine and at the Louis D. Brandeis School of Law. Professor Rothstein is a leading authority on genetics, privacy, and health policy. He has served as an advisor to the NIH, CDC, DOE, Institute of Medicine, National Conference of State Legislatures, and numerous other public and professional entitles.

Von der hinteren Coverseite

"In this remarkably broad and far-reaching work, editor Mark Rothstein and his distinguished list of contributors have laid out an impressive framework for the field. Beginning with a survey of public attitudes, and progressing through scientific, clinical, governmental, legal, economic, and societal issues, the text builds to a final provocative epilogue on consequences for public policy."
-from the Foreword by Francis S. Collins

Pharmacogenomics promises to revolutionize medicine by enabling the prevention, diagnosis, and treatment of diseases at the genome level. While a substantial amount of public and private research focuses on new pharmacogenomic applications, notably less attention has been directed to the ethical, legal, and social implications of "individualized medicine." Mark Rothstein's timely anthology reduces that scholarship deficit, presenting a multidisciplinary analysis of the scientific, clinical, economic, ethical, social, and legal implications of pharmacogenomics.

Assembling an all-star cast of bioethical scholars, medical researchers, legal scholars, and social scientists, Mark Rothstein examines the promises, questions, and concerns these revolutionary therapies implicitly present. Among other features, Pharmacogenomics:
* Reports for the first time the results of the first detailed, national survey of public attitudes regarding pharmacogenomics
* Covers informed consent, privacy, confidentiality, and risk-benefit evaluations
* Analyzes the potentially enormous changes in the standard of care and the approach to treatment with the development and application of pharmacogenomic technology
* Addresses practical considerations of education, training, oversight, guidelines and protocols, and continuing education requirements
* Recommends approaches to respond to the more complex issues of safety, efficacy, and quality in the distribution and development of individualized therapies
* Explores the new legal standards and implementation challenges
* Offers a policy framework that balances the benefits and risks and considers the wide range of legislative, regulatory, and professional options

Biotechnology and pharmaceutical researchers and regulators, health care professionals and students, and academics and policymakers will find Pharmacogenomics to be a valuable resource.

Aus dem Klappentext

"In this remarkably broad and far-reaching work, editor Mark Rothstein and his distinguished list of contributors have laid out an impressive framework for the field. Beginning with a survey of public attitudes, and progressing through scientific, clinical, governmental, legal, economic, and societal issues, the text builds to a final provocative epilogue on consequences for public policy."
-from the Foreword by Francis S. Collins

Pharmacogenomics promises to revolutionize medicine by enabling the prevention, diagnosis, and treatment of diseases at the genome level. While a substantial amount of public and private research focuses on new pharmacogenomic applications, notably less attention has been directed to the ethical, legal, and social implications of "individualized medicine." Mark Rothstein's timely anthology reduces that scholarship deficit, presenting a multidisciplinary analysis of the scientific, clinical, economic, ethical, social, and legal implications of pharmacogenomics.

Assembling an all-star cast of bioethical scholars, medical researchers, legal scholars, and social scientists, Mark Rothstein examines the promises, questions, and concerns these revolutionary therapies implicitly present. Among other features, Pharmacogenomics:
* Reports for the first time the results of the first detailed, national survey of public attitudes regarding pharmacogenomics
* Covers informed consent, privacy, confidentiality, and risk-benefit evaluations
* Analyzes the potentially enormous changes in the standard of care and the approach to treatment with the development and application of pharmacogenomic technology
* Addresses practical considerations of education, training, oversight, guidelines and protocols, and continuing education requirements
* Recommends approaches to respond to the more complex issues of safety, efficacy, and quality in the distribution and development of individualized therapies
* Explores the new legal standards and implementation challenges
* Offers a policy framework that balances the benefits and risks and considers the wide range of legislative, regulatory, and professional options

Biotechnology and pharmaceutical researchers and regulators, health care professionals and students, and academics and policymakers will find Pharmacogenomics to be a valuable resource.

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

Verlag
Wiley-Liss
Erscheinungsdatum
2003
Sprache
Englisch
ISBN 10 
0471227692
ISBN 13 
9780471227694
Einband
Gebundene Ausgabe
Auflage
1
Anzahl der Seiten
384
Herausgeber
Rothstein Mark A.
Kontakt zum Hersteller
Wiley-VCH GmbH
product_safety@wiley.com

Boschstrasse 12
Weinheim
69469
Deutschland

Weitere beliebte Ausgaben desselben Titels

9780471426134: Pharmacogenomics: Social, Ethical, and Clinical Dimensions

Vorgestellte Ausgabe

ISBN 10:  047142613X ISBN 13:  9780471426134
Softcover